Two Sigma Advisers’s Cytek Biosciences CTKB Stock Holding History

Two Sigma Advisers’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-61,600	Closed	-$214K	–	2405
2025 Q3	$214K	Buy	+61,600	New	+$231K	﹤0.01%	2111
2022 Q2	–	Sell	-95,000	Closed	-$1.02M	–	2698
2022 Q1	$1.02M	Buy	+95,000	New	+$1.28M	﹤0.01%	1627

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Two Sigma Advisers's CTKB Position: Q4 2025 in Review

Two Sigma Advisers sold out of Cytek Biosciences (CTKB) in Q4 2025, closing a stake of 61,600 shares — an estimated $214K sold.

Two Sigma Advisers first reported a position in CTKB in Q1 2022 and held it in 2 quarters. The position peaked at $1.02M in Q1 2022. 155 funds tracked by Wall St. Rank hold CTKB as of Q4 2025.

Two Sigma Advisers reported no remaining Cytek Biosciences position as of Q4 2025 after selling out during the quarter.
Two Sigma Advisers sold 61,600 Cytek Biosciences shares in Q4 2025, an estimated $214K.
Two Sigma Advisers first reported a position in Cytek Biosciences in Q1 2022 and held it in 2 quarters.
Two Sigma Advisers's Cytek Biosciences position peaked at $1.02M in Q1 2022.
155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2025.

Based on Two Sigma Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.